These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9112304)

  • 41. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis.
    Nuovo J; Melnikow J; Paliescheskey M; King J; Mowers R
    J Am Board Fam Pract; 1995; 8(1):7-16. PubMed ID: 7701965
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dirithromycin: a new macrolide.
    Wintermeyer SM; Abdel-Rahman SM; Nahata MC
    Ann Pharmacother; 1996 Oct; 30(10):1141-9. PubMed ID: 8893122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative efficacy and toxicity of roxithromycin and erythromycin ethylsuccinate in the treatment of streptococcal pharyngitis in adults.
    Melcher GP; Hadfield TL; Gaines JK; Winn RE
    J Antimicrob Chemother; 1988 Oct; 22(4):549-56. PubMed ID: 3060461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Agranulocytosis induced by macrolide antibiotics.
    Tanaka M; Tao T; Kaku K; Kaneko T
    Am J Hematol; 1995 Feb; 48(2):133. PubMed ID: 7847332
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical efficacy of roxithromycin in respiratory tract infections.
    Ludwig E; Graber H; Bárándy Z; Lányi
    J Chemother; 1989 Jul; 1(4 Suppl):796-7. PubMed ID: 16312644
    [No Abstract]   [Full Text] [Related]  

  • 46. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin.
    Bahal N; Nahata MC
    Ann Pharmacother; 1992 Jan; 26(1):46-55. PubMed ID: 1318761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic therapy of ocular and cutaneous rosacea in children.
    Gonser LI; Gonser CE; Deuter C; Heister M; Zierhut M; Schaller M
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1732-1738. PubMed ID: 28621909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial.
    Wiesli P; Czerwenka W; Meniconi A; Maly FE; Hoffmann U; Vetter W; Schulthess G
    Circulation; 2002 Jun; 105(22):2646-52. PubMed ID: 12045171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nail pigmentation due to roxithromycin.
    Dawn G; Kanwar AJ; Dhar S
    Dermatology; 1995; 191(4):342-3. PubMed ID: 8573939
    [No Abstract]   [Full Text] [Related]  

  • 50. [Treatment of acute and bacterial lower respiratory tract infections with roxithromycin].
    Chabbou A; Belalgia S; Kamel A; Megdiche L
    Tunis Med; 1992 Oct; 70(10):467-71. PubMed ID: 1295159
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparison of two oral forms of erythromycin in the treatment of acute respiratory tract infections. A multicentre general practice study.
    Macklin J; Barden R; Coles S
    J Int Med Res; 1989; 17(3):287-94. PubMed ID: 2670633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fulminant hepatic failure associated with intravenous erythromycin lactobionate.
    Gholson CF; Warren GH
    Arch Intern Med; 1990 Jan; 150(1):215-6. PubMed ID: 2297290
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Roxithromycin compared with erythromycin against genitourinary chlamydial infections.
    Worm AM; Hoff G; Kroon S; Petersen CS; Christensen JJ
    Genitourin Med; 1989 Jan; 65(1):35-8. PubMed ID: 2646206
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors.
    Portier H; Brambilla C; Garre M; Paganin F; Poubeau P; Zuck P
    Eur J Clin Microbiol Infect Dis; 2005 Jun; 24(6):367-76. PubMed ID: 15944847
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection.
    Nakamura H; Fujishima S; Inoue T; Ohkubo Y; Soejima K; Waki Y; Mori M; Urano T; Sakamaki F; Tasaka S; Ishizaka A; Kanazawa M; Yamaguchi K
    Eur Respir J; 1999 Jun; 13(6):1371-9. PubMed ID: 10445614
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical and financial impact of intravenous erythromycin therapy in hospitalized patients.
    Classen DC; Burke JP; Pestotnik SL; Lloyd JF
    Ann Pharmacother; 1999 Jun; 33(6):669-73. PubMed ID: 10410176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Otitis media-related antibiotic prescribing patterns, outcomes, and expenditures in a pediatric medicaid population.
    Berman S; Byrns PJ; Bondy J; Smith PJ; Lezotte D
    Pediatrics; 1997 Oct; 100(4):585-92. PubMed ID: 9310510
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experience with roxithromycin in visceral leishmaniasis in north Bihar.
    Lal SK; Lal R; Lal S; Lal R; Lal BN
    J Assoc Physicians India; 1996 Sep; 44(9):615-7. PubMed ID: 9251373
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Influence of macrolide therapy on microorganism of chronic respiratory tract infections].
    Okimoto N; Osaki K; Honda Y; Sunagawa T; Asaoka N; Ohba H; Yoneyama H; Soejima R
    Kansenshogaku Zasshi; 2000 Oct; 74(10):846-8. PubMed ID: 11109768
    [No Abstract]   [Full Text] [Related]  

  • 60. A new macrolide, TE-031 (A-56268), in treatment of experimental Legionnaires' disease.
    Kohno S; Koga H; Yamaguchi K; Masaki M; Inoue Y; Dotsu Y; Masuyama Y; Hayashi T; Hirota M; Saito A
    J Antimicrob Chemother; 1989 Sep; 24(3):397-405. PubMed ID: 2530201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.